AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 261 min read$CRD-A

Bart Andrew John sold $21K of CRD-A

Bart Andrew John (Executive Vice President) sold 1,995 shares of CRAWFORD & CO (CRD-A) at $10.37 on 2026-05-22.

Original reporting
SEC EDGAR · Bart Andrew John
Published May 26, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 6:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRD-A
Neutral
low confidence
Mentioned
$CRD-A
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRD-ANeutralLow
01

Why it matters

Insider sale disclosures can influence short-term sentiment, but without additional company-specific catalysts they typically have low trading impact.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is not a fundamental catalyst.

03

What to watch

The sale is explicitly open-market and not tied to a 10b5-1 plan per the filing, so interpretation should be cautious and context-dependent.

Relevance 6/10Timing: Immediate for monitoring flows/sentiment; not a catalyst for fundamentals.

Background

The article is an SEC Form 4 insider transaction disclosure for Crawford & Co (CRD-A).

Company-level read

Ticker impact

$CRD-ANeutralLow confidence
Context

SEC Form 4 shows executive vice president Bart Andrew John sold 1,995 shares of Crawford & Co at $10.3721 on 2026-05-22.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing reports a small, pre-plan-noted sale with no accompanying company news (earnings, contracts, litigation, or guidance changes).

Market effects

Sector

Minimal—no sector-wide signal beyond routine insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider selling can reflect diversification, taxes, or routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Crawford & Co

    Subject of the SEC Form 4 insider transaction; executive vice president sold shares on 2026-05-22.

  • insider
    Bart Andrew John

    Executive vice president who reported an open-market sale of 1,995 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRD-A insider trading history →

Related articles

NOV 2
$CRD-AMedAI 8/10

Crawford & Company Reports 2026 Third Quarter Results

Crawford & Company (CRD-A, CRD-B) reported Q3 2026 revenues of $321.6M, down slightly from $322.2M in Q3 2025. Net income rose to $15.0M ($0.31 per share) from $12.4M ($0.25 per share). International operations drove improved performance, while U.S. segments saw declines. The CEO highlighted progress in cost management and client relationships, but expects fourth-quarter pressure from lower claims frequency.

saultstar.com6 min
AUG 3
$CRD-AMed

CRAWFORD & COMPANY REPORTS 2026 SECOND QUARTER RESULTS

CRAWFORD & CO (CRD-A) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Crawford & Company® 5335 Triangle Parkway Peachtree Corners, GA 30092 FOR IMMEDIATE RELEASE CRAWFORD & COMPANY REPORTS 2026 SECOND QUARTER RESULTS Strong Earnings Growth Driven by International Operations and Broadspire Quarterly Dividend Increases to $0.08 per Share

SEC EDGAR 8-K6 min
NOV 3
$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min
NOV 3
$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min